PetVivo Holdings (PETV)
OTHER OTC:PETV
Want to see PETV full AI Analyst Report?
PETV Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EST
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.49 - $1.69
Previous CloseN/A
Volume249.00
Average Volume (3M)21.60K
Market Cap
$27.98M
Enterprise Value$21.72M
Total Cash (Recent Filing)$168.16K
Total Debt (Recent Filing)$70.56K
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding35,017,418
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.91
Price to Sales (P/S)10.86
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue19.53
Enterprise Value/Gross Profit29.58
Enterprise Value/Ebitda-2.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High‑margin Recurring SaaS OpportunityThe exclusive AI licensing and PetVivo AI SaaS create a durable, recurring revenue stream with very high gross margins and low CapEx. Over 2–6 months this structurally diversifies revenue away from single product sales, improving long‑term margin sustainability if subscription adoption scales.
Broad Distribution And International ExpansionLarge channel deals and initial international distributors materially expand addressable market and lower customer acquisition friction. Durable partnerships (VGP, U.K., Mexico) accelerate adoption of Spryng and PrecisePRP and support sustained revenue growth as commercialization execution continues.
Low Leverage And Materially Reduced LiabilitiesSharp liability reductions and minimal debt provide financial flexibility, lowering default risk and freeing capacity to invest in commercialization or AI rollout. This stronger balance sheet base is a durable enabler for execution without immediate refinancing pressure.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow indicates ongoing cash burn that will require continued financing. Over months this constrains investment in sales, R&D, and commercialization, increases dilution risk, and limits the company's ability to self‑fund a scaling SaaS or device roll‑out.
Deep Unprofitability And Negative MarginsExtremely large operating and net losses create a long path to profitability; even with high gross margins, fixed operating costs overwhelm current revenue. This structural loss profile pressures returns, investor patience, and requires successful SaaS monetization or sales growth to change trajectory.
Declining Revenue Base And Timing UncertaintyA materially shrinking revenue base undermines operating leverage and makes scale economics harder. Combined with management's note that AI revenue won't contribute until next fiscal year, this creates durable visibility risk: growth depends on timely conversion of new channels and SaaS monetization.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.49 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $27.98M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Jun 25, 2026 which is in 68 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Feb 17, 2026. The company reported -$0.069 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.069.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 35,017,418 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.881%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PetVivo Holdings
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PETV Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive strategic and operational narrative: management secured transformative partnerships (exclusive AI licensing, major distributor and channel agreements), advanced R&D and international commercialization (Health Canada recognition, U.K. and Mexico distribution), and materially reduced liabilities (≈81% decline). These developments position the company for a recurring, high-margin SaaS revenue stream (PetVivo AI) that could complement device and biologic sales. Near-term financials remain challenging — modest revenue decline (−2% YoY for nine months), lower gross margins from product mix, ongoing operating losses (net loss $7.5M) and cash burn ($5.3M) leave liquidity and timing risks. Overall, the strategic progress and balance sheet improvements outweigh the current financial headwinds, suggesting a Positive sentiment with execution and monetization of AI and commercialization plans as key drivers to watch.View all PETV earnings summariesTechnical Analysis
Iridex
―
Lifeward
―
Vivos Therapeutics
―
Allurion Technologies
―
Nexalin Technology, Inc.
―
Ownership Overview
41.04% Insiders
0.37% Other Institutional Investors
58.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---